Medicine
Eptifibatide 75 mg/100 mL injection
Eptifibatide 75 mg/100 mL injection is a generic prescription medicine for intravenous use, made by 8 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Key facts
- Active ingredient (INN)
- Eptifibatide
- Brand
- Sold under the generic name
- Strength
- 75 mg/100 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 100 mL, 100 mL and 7 more
- Manufacturers
- EugiaIndiaMylan InstitutionalSlate Run PharmaceuticalsAvenacyBaxter HealthcareHainan Shuangcheng PharmaceuticalsMeitheal PharmaceuticalsSagent Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B01AC16 Eptifibatide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 December 2015
- Identifiers
- RxCUI 200349, 1736470, 1736477DailyMed set ID a7a89c59-22fb-41fd-b70a-ac2395717db1, 88a37f9c-496b-4a6b-9665-4550abba04f1, 3e7e7cd3-8efa-4d91-a5ab-7fd78b0cc65e +7NDC 72078-026, 67457-631, 71288-413 +7Application ANDA203258, ANDA213599, ANDA209864 +4
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 100 mL in 1 vial, single-dose | 55150-218-99 | EugiaIndia | 8 December 2015 |
| 1 vial in 1 carton / 100 mL in 1 vial | 67457-631-10 | Mylan Institutional | 13 December 2018 |
| 1 vial in 1 carton / 100 mL in 1 vial | 72078-026-10 | Mylan Institutional | 20 November 2020 |
| 100 mL in 1 vial | 70436-027-80 | Slate Run Pharmaceuticals | 22 July 2019 |
| 100 mL in 1 vial | 70436-163-80 | Slate Run Pharmaceuticals | 1 December 2020 |
| 1 vial, single-dose in 1 carton / 100 mL in 1 vial, single-dose | 0338-9558-10 | Baxter Healthcare | 1 February 2019 |
| 1 vial, single-dose in 1 carton / 100 mL in 1 vial, single-dose | 52958-040-01 | Hainan Shuangcheng Pharmaceuticals | 21 April 2022 |
| 1 vial, single-dose in 1 carton / 100 mL in 1 vial, single-dose | 71288-413-51 | Meitheal Pharmaceuticals | 9 May 2024 |
| 1 vial in 1 carton / 100 mL in 1 vial | 25021-408-51 | Sagent Pharmaceuticals | 15 July 2018 |
| 1 vial, single-dose in 1 carton / 100 mL in 1 vial, single-dose | 83634-301-51 | Avenacy | 31 January 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Eptifibatide
Clinical summary
Eptifibatide is a platelet aggregation inhibitor indicated for treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI), among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Eptifibatide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EptifibatideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Eptifibatide prescribing information (Avenacy) · U.S. National Library of Medicine, DailyMed
- Eptifibatide Accord: European public assessment report (EPAR) · European Medicines Agency
Need Eptifibatide 75 mg/100 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.